Turek M D, Baird W M
Ingham Center for Analgesic Development, Lansing, MI 48910-2819.
J Clin Pharmacol. 1988 Dec;28(s1):S23-8. doi: 10.1002/j.1552-4604.1988.tb05973.x.
One hundred sixty-one patients with postoperative pain were treated at a single center in a double-blind, randomized, parallel study designed to compare the efficacy and safety of single oral doses of ketoprofen (50 and 150 mg), an acetaminophen (650 mg) plus codeine (60 mg) combination, and placebo. From 1 through 4 hours after administration of the study drugs, the mean summed pain intensity difference (SPID) and time-weighted total pain relief (TOPAR) scores for the three active treatments generally were significantly (P less than 0.05) higher than those for placebo but not significantly different from each other. At the 6-hour evaluation, the ketoprofen groups, but not the acetaminophen-codeine group, had higher (P less than 0.05) mean SPID and TOPAR scores than the placebo group, as a result of a shorter duration of pain relief in the acetaminophen-codeine group. The 6-hour TOPAR scores were significantly (P less than 0.05) higher for both ketoprofen groups than for the acetaminophen-codeine group; the ketoprofen 150 mg group also had significantly (P less than 0.05) higher mean 6-hour SPID and global subjective assessment scores. As a result of a higher frequency of somnolence, there was a significantly (P less than 0.05) greater incidence of central nervous system adverse drug reactions among patients treated with acetaminophen plus codeine than among those treated with 150 mg of ketoprofen. These results indicate that the analgesic efficacy of both 50 and 150 mg doses of ketoprofen equals that of acetaminophen 650 mg plus codeine 60 mg and the duration of the analgesic effect of ketoprofen is significantly longer.
在一项双盲、随机、平行研究中,一家中心对161例术后疼痛患者进行了治疗,该研究旨在比较单次口服酮洛芬(50毫克和150毫克)、对乙酰氨基酚(650毫克)加可待因(60毫克)组合以及安慰剂的疗效和安全性。在服用研究药物后的1至4小时内,三种活性治疗的平均疼痛强度差值总和(SPID)和时间加权总疼痛缓解(TOPAR)评分总体上显著高于安慰剂组(P小于0.05),但彼此之间无显著差异。在6小时评估时,酮洛芬组(而非对乙酰氨基酚 - 可待因组)的平均SPID和TOPAR评分高于安慰剂组(P小于0.05),这是因为对乙酰氨基酚 - 可待因组的疼痛缓解持续时间较短。两个酮洛芬组的6小时TOPAR评分均显著高于对乙酰氨基酚 - 可待因组(P小于0.05);酮洛芬150毫克组的平均6小时SPID和总体主观评估评分也显著更高(P小于0.05)。由于嗜睡发生率较高,与接受150毫克酮洛芬治疗的患者相比,接受对乙酰氨基酚加可待因治疗的患者中枢神经系统药物不良反应的发生率显著更高(P小于0.05)。这些结果表明,50毫克和150毫克剂量的酮洛芬的镇痛效果等同于650毫克对乙酰氨基酚加60毫克可待因,且酮洛芬的镇痛作用持续时间显著更长。